{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T23:46:07Z","timestamp":1767915967411,"version":"3.49.0"},"reference-count":25,"publisher":"American Diabetes Association","issue":"4","license":[{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":4234,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,4,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>Insulin resistance might play a role in the pathogenesis of polycystic ovarian syndrome (PCOS). The family of glycoprotein 130 (gp130) cytokines could influence insulin action. One of these cytokines is interleukin (IL)-6, which exerts a short-term insulin-sensitizing effect, whereas in a long-term period, it might induce insulin resistance. Some other gp130 activators are supposed to have beneficial metabolic effects. Gp130 is present in the circulation in the soluble form (sgp130), which inhibits intracellular gp130 signaling. The aim of the present study was to estimate the relation between sgp130 and insulin sensitivity in women with PCOS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>We studied 78 women with PCOS (35 lean and 43 obese) and 34 healthy women (18 lean and 16 obese). The euglycemic-hyperinsulinemic clamp and the measurements of serum sgp130, IL-6, soluble IL-6 receptor (sIL-6R), and sex hormones were performed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Both obesity and PCOS were characterized by an increased sgp130 (P &amp;lt; 0.0001 and P = 0.0002, respectively). sIL-6R concentration was lower (P = 0.0036) in women with PCOS independently of obesity. Serum sgp130 was negatively correlated with insulin sensitivity when control and PCOS women were analyzed together (r = \u22120.36, P &amp;lt; 0.0001) and in the PCOS subjects separately (r = \u22120.34, P = 0.002). In multiple regression analysis, this correlation was significant after adjustment for BMI, waist, percent of body fat, postload glucose and insulin, triglycerides, and high-sensitive C-reactive protein.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Serum sgp130 is inversely and independently associated with insulin sensitivity in women with PCOS. An increased serum sgp130 in obesity and PCOS suggests an inhibition of intracellular gp130 signaling in insulin-resistant conditions.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/db09-1316","type":"journal-article","created":{"date-parts":[[2010,1,27]],"date-time":"2010-01-27T05:00:28Z","timestamp":1264568428000},"page":"1026-1029","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":22,"title":["Serum Soluble Glycoprotein 130 Concentration Is Inversely Related to Insulin Sensitivity in Women With Polycystic Ovary Syndrome"],"prefix":"10.2337","volume":"59","author":[{"given":"Agnieszka","family":"Nikolajuk","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Diabetology, and Internal Medicine, Medical University of Bialystok, Bialystok, Poland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Kowalska","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology, and Internal Medicine, Medical University of Bialystok, Bialystok, Poland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Karczewska-Kupczewska","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology, and Internal Medicine, Medical University of Bialystok, Bialystok, Poland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Adamska","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology, and Internal Medicine, Medical University of Bialystok, Bialystok, Poland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elzbieta","family":"Otziomek","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology, and Internal Medicine, Medical University of Bialystok, Bialystok, Poland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Slawomir","family":"Wolczynski","sequence":"additional","affiliation":[{"name":"Department of Reproduction and Gynecological Endocrinology, Medical University of Bialystok, Bialystok, Poland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida","family":"Kinalska","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology, and Internal Medicine, Medical University of Bialystok, Bialystok, Poland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Gorska","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology, and Internal Medicine, Medical University of Bialystok, Bialystok, Poland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Straczkowski","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology, and Internal Medicine, Medical University of Bialystok, Bialystok, Poland;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2010,1,26]]},"reference":[{"key":"2022031222462938300_B1","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1210\/jcem.84.11.6148","article-title":"A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile","volume":"84","author":"Diamanti-Kandarakis","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031222462938300_B2","first-page":"2434","article-title":"A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain","volume":"85","author":"Asunci\u00f3n","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031222462938300_B3","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1210\/jcem.84.6.5803","article-title":"Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women","volume":"84","author":"Carmina","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031222462938300_B4","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1172\/JCI30453","article-title":"gp130 receptor ligands as potential therapeutic targets for obesity","volume":"117","author":"Febbraio","year":"2007","journal-title":"J Clin Invest"},{"key":"2022031222462938300_B5","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/stem.5530120303","article-title":"Signal transduction through gp130 that is shared among the receptors for the interleukin 6 related cytokine subfamily","volume":"12","author":"Hirano","year":"1994","journal-title":"Stem Cells"},{"key":"2022031222462938300_B6","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1146\/annurev.immunol.15.1.797","article-title":"gp130 and the interleukin-6 family of cytokines","volume":"15","author":"Taga","year":"1997","journal-title":"Annu Rev Immunol"},{"key":"2022031222462938300_B7","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.2337\/diabetes.51.12.3391","article-title":"Interleukin-6 induces cellular insulin resistance in hepatocytes","volume":"51","author":"Senn","year":"2002","journal-title":"Diabetes"},{"key":"2022031222462938300_B8","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s00125-004-1447-y","article-title":"Interleukin-6 and insulin sensitivity: friend or foe?","volume":"47","author":"Carey","year":"2004","journal-title":"Diabetologia"},{"key":"2022031222462938300_B9","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1210\/me.2005-0490","article-title":"Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle","volume":"20","author":"Al-Khalili","year":"2006","journal-title":"Mol Endocrinol"},{"key":"2022031222462938300_B10","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nm1383","article-title":"CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK","volume":"12","author":"Watt","year":"2006","journal-title":"Nat Med"},{"key":"2022031222462938300_B11","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.V82.4.1120.1120","article-title":"Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130","volume":"82","author":"Narazaki","year":"1993","journal-title":"Blood"},{"key":"2022031222462938300_B12","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1084\/jem.183.4.1399","article-title":"The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6","volume":"183","author":"Peters","year":"1996","journal-title":"J Exp Med"},{"key":"2022031222462938300_B13","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/jir.2005.25.241","article-title":"IL-6 transsignaling: the in vivo consequences","volume":"25","author":"Jones","year":"2005","journal-title":"J Interferon Cytokine Res"},{"key":"2022031222462938300_B14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1189\/jlb.1105674","article-title":"Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer","volume":"80","author":"Rose-John","year":"2006","journal-title":"J Leuk Biol"},{"key":"2022031222462938300_B15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/humrep\/deh098","article-title":"Revised 2003 consensus on diagnostic criteria and long term health risk related to polycystic ovary syndrome (PCOS)","volume":"19","author":"The Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group","year":"2004","journal-title":"Hum Rep"},{"key":"2022031222462938300_B16","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1093\/humrep\/dem118","article-title":"Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome","volume":"22","author":"Kowalska","year":"2007","journal-title":"Hum Rep"},{"key":"2022031222462938300_B17","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1210\/jcem.84.10.6079","article-title":"A critical evaluation of simple methods for the estimation of free testosterone in serum","volume":"84","author":"Vermeulen","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031222462938300_B18","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/oby.2003.136","article-title":"Association of polymorphisms in the interleukin 6 receptor complex with obesity and hyperandrogenism","volume":"11","author":"Escobar-Morreale","year":"2003","journal-title":"Obesity Res"},{"key":"2022031222462938300_B19","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.fertnstert.2004.01.021","article-title":"A common interleukin-6 gene promoter polymorphism influences the clinical characteristics of women with polycystic ovary syndrome","volume":"81","author":"Walch","year":"2004","journal-title":"Fertil Steril"},{"key":"2022031222462938300_B20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/oby.2007.28","article-title":"A polymorphism at the IL6ST (gp130) locus is associated with traits of the metabolic syndrome","volume":"16","author":"Gottardo","year":"2008","journal-title":"Obesity"},{"key":"2022031222462938300_B21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s102380300012","article-title":"The critical role of interleukin-6 and interleukin-6 soluble receptor in human follicular fluids","volume":"3","author":"Kawasaki","year":"2003","journal-title":"Clin Exp Med"},{"key":"2022031222462938300_B22","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.metabol.2009.02.022","article-title":"Evidence of proatherogenic inflammation in polycystic ovary syndrome","volume":"58","author":"Gonz\u00e1lez","year":"2009","journal-title":"Metabolism"},{"key":"2022031222462938300_B23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00125-003-1090-z","article-title":"Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women","volume":"46","author":"Escobar-Morreale","year":"2003","journal-title":"Diabetologia"},{"key":"2022031222462938300_B24","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1530\/eje.0.1500525","article-title":"The polycystic ovary syndrome per se is not associated with increased chronic inflammation","volume":"150","author":"M\u00f6hlig","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"2022031222462938300_B25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1365-2265.2006.02553.x","article-title":"Polymorphisms in interleukin-6 receptor gene are associated with body mass index and with characteristics of the metabolic syndrome","volume":"65","author":"Esteve","year":"2006","journal-title":"Clin Endocrinol"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/59\/4\/1026\/395111\/zdb00410001026.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/59\/4\/1026\/395111\/zdb00410001026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:20:56Z","timestamp":1667406056000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/59\/4\/1026\/33329\/Serum-Soluble-Glycoprotein-130-Concentration-Is"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,26]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2010,1,26]]},"published-print":{"date-parts":[[2010,4,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db09-1316","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,26]]}}}